Published in Annu Rev Neurosci on January 01, 2001
Davunetide (AL-108) in Predicted Tauopathies - Pilot Study | NCT01056965
Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. J Neurosci (2009) 12.05
Pathways towards and away from Alzheimer's disease. Nature (2004) 8.72
GSK3 takes centre stage more than 20 years after its discovery. Biochem J (2001) 7.74
Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol (2009) 7.50
Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem (2009) 5.76
Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature (2013) 3.55
Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med (2012) 3.31
Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases. Microbiol Mol Biol Rev (2006) 3.30
Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med (2011) 3.28
Distinct α-synuclein strains differentially promote tau inclusions in neurons. Cell (2013) 3.24
Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A (2011) 3.11
Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. J Neurosci (2013) 2.90
The many faces of tau. Neuron (2011) 2.89
Divergence of human and mouse brain transcriptome highlights Alzheimer disease pathways. Proc Natl Acad Sci U S A (2010) 2.85
Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron (2014) 2.83
The MAP2/Tau family of microtubule-associated proteins. Genome Biol (2004) 2.80
Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest (2004) 2.80
Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol (2009) 2.76
Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing. Hum Mol Genet (2009) 2.69
O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 2.67
Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci U S A (2004) 2.48
Advances in understanding the molecular basis of frontotemporal dementia. Nat Rev Neurol (2012) 2.48
Chaperones increase association of tau protein with microtubules. Proc Natl Acad Sci U S A (2003) 2.32
The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention. Neurochem Int (2007) 2.11
Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov (2009) 2.08
Repeat motifs of tau bind to the insides of microtubules in the absence of taxol. EMBO J (2003) 2.07
Differential regulation of microtubule dynamics by three- and four-repeat tau: implications for the onset of neurodegenerative disease. Proc Natl Acad Sci U S A (2003) 2.06
Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci U S A (2009) 2.04
Olfactory dysfunction correlates with amyloid-beta burden in an Alzheimer's disease mouse model. J Neurosci (2010) 2.02
The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun (2011) 2.00
In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci (2011) 2.00
Prolyl isomerase Pin1 as a molecular switch to determine the fate of phosphoproteins. Trends Biochem Sci (2011) 1.98
Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease. Ann Neurol (2007) 1.92
Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum Mol Genet (2010) 1.90
Template-assisted filament growth by parallel stacking of tau. Proc Natl Acad Sci U S A (2004) 1.89
Tau promotes neurodegeneration through global chromatin relaxation. Nat Neurosci (2014) 1.87
Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr Med Chem (2008) 1.84
GABAergic interneuron dysfunction impairs hippocampal neurogenesis in adult apolipoprotein E4 knockin mice. Cell Stem Cell (2009) 1.84
Alzheimer's disease. Cold Spring Harb Perspect Biol (2011) 1.81
Linking axonal degeneration to microtubule remodeling by Spastin-mediated microtubule severing. J Cell Biol (2005) 1.80
Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proc Natl Acad Sci U S A (2007) 1.77
Tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid. J Cell Biol (2006) 1.77
Neuroinflammatory processes in Alzheimer's disease. J Neural Transm (Vienna) (2010) 1.73
Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease. J Biol Chem (2011) 1.71
Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J (2012) 1.70
The genetics of Parkinson disease. J Geriatr Psychiatry Neurol (2010) 1.69
Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harb Perspect Med (2011) 1.68
From Alzheimer to Huntington: why is a structural understanding so difficult? EMBO J (2003) 1.68
Drosophila models of neurodegenerative diseases. Annu Rev Pathol (2009) 1.67
Genome-wide screen for modifiers of ataxin-3 neurodegeneration in Drosophila. PLoS Genet (2007) 1.66
Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc Natl Acad Sci U S A (2008) 1.64
Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. J Neurosci (2010) 1.60
The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci (2012) 1.60
Inhibition and modulation of gamma-secretase for Alzheimer's disease. Neurotherapeutics (2008) 1.55
Dementia induces correlated reductions in white matter integrity and cortical thickness: a multivariate neuroimaging study with sparse canonical correlation analysis. Neuroimage (2010) 1.54
alpha-internexin is present in the pathological inclusions of neuronal intermediate filament inclusion disease. Am J Pathol (2004) 1.53
Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat Rev Neurosci (2015) 1.53
Aberrant lysosomal carbohydrate storage accompanies endocytic defects and neurodegeneration in Drosophila benchwarmer. J Cell Biol (2005) 1.52
Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev (2013) 1.52
Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol (2013) 1.51
Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model. Proc Natl Acad Sci U S A (2007) 1.50
MARK/PAR1 kinase is a regulator of microtubule-dependent transport in axons. J Cell Biol (2004) 1.49
Protein homeostasis in models of aging and age-related conformational disease. Adv Exp Med Biol (2010) 1.48
Tau overexpression impacts a neuroinflammation gene expression network perturbed in Alzheimer's disease. PLoS One (2014) 1.46
Genomic features defining exonic variants that modulate splicing. Genome Biol (2010) 1.46
Apolipoprotein e sets the stage: response to injury triggers neuropathology. Neuron (2012) 1.46
DNA replication stress is a determinant of chronological lifespan in budding yeast. PLoS One (2007) 1.46
Tau Prion Strains Dictate Patterns of Cell Pathology, Progression Rate, and Regional Vulnerability In Vivo. Neuron (2016) 1.45
Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice. BMC Neurosci (2008) 1.44
alpha-Internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases. Acta Neuropathol (2004) 1.43
Evidence that non-fibrillar tau causes pathology linked to neurodegeneration and behavioral impairments. J Alzheimers Dis (2008) 1.43
Nucleation-dependent tau filament formation: the importance of dimerization and an estimation of elementary rate constants. J Biol Chem (2008) 1.42
Parkin mediates the degradation-independent ubiquitination of Hsp70. J Neurochem (2008) 1.42
Leptin: a novel therapeutic strategy for Alzheimer's disease. J Alzheimers Dis (2009) 1.42
Tau Pathology Induces Excitatory Neuron Loss, Grid Cell Dysfunction, and Spatial Memory Deficits Reminiscent of Early Alzheimer's Disease. Neuron (2017) 1.41
Phosphorylation of tau antagonizes apoptosis by stabilizing beta-catenin, a mechanism involved in Alzheimer's neurodegeneration. Proc Natl Acad Sci U S A (2007) 1.41
Oxidative stress mediates tau-induced neurodegeneration in Drosophila. J Clin Invest (2006) 1.40
Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol Ther (2010) 1.39
Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. Brain (2012) 1.38
Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. Mol Biol Cell (2007) 1.37
Pin1 has opposite effects on wild-type and P301L tau stability and tauopathy. J Clin Invest (2008) 1.37
Induction of intracellular tau aggregation is promoted by α-synuclein seeds and provides novel insights into the hyperphosphorylation of tau. J Neurosci (2011) 1.35
The cytoskeleton in neurodegenerative diseases. J Pathol (2004) 1.35
LRRK2 kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the Drosophila neuromuscular junction. J Neurosci (2010) 1.35
Structural and functional changes in tau mutant mice neurons are not linked to the presence of NFTs. Exp Neurol (2009) 1.35
Filamentous tau in oligodendrocytes and astrocytes of transgenic mice expressing the human tau isoform with the P301L mutation. Am J Pathol (2003) 1.34
Alzheimer's disease and the amyloid-beta peptide. J Alzheimers Dis (2010) 1.33
Interaction of tau protein with the dynactin complex. EMBO J (2007) 1.33
Drosophila melanogaster in the study of human neurodegeneration. CNS Neurol Disord Drug Targets (2010) 1.33
A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. Acta Neuropathol (2014) 1.32
Analysis of tau phosphorylation and truncation in a mouse model of human tauopathy. Am J Pathol (2007) 1.32
Retracted Intraneuronal APP, not free Aβ peptides in 3xTg-AD mice: implications for tau versus Aβ-mediated Alzheimer neurodegeneration. J Neurosci (2011) 1.31
The involvement of microRNAs in neurodegenerative diseases. Front Cell Neurosci (2013) 1.30
Tau isoform regulation is region- and cell-specific in mouse brain. J Comp Neurol (2008) 1.29
Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry (2009) 1.28
Cytoskeletal pathologies of Alzheimer disease. Cell Motil Cytoskeleton (2009) 1.28
Signature tau neuropathology in gray and white matter of corticobasal degeneration. Am J Pathol (2002) 1.28
Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proc Natl Acad Sci U S A (2003) 1.27
Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles. Nucleic Acids Res (2004) 1.27
Tauopathy with paired helical filaments in an aged chimpanzee. J Comp Neurol (2008) 1.27
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
Alpha-synuclein in Lewy bodies. Nature (1997) 20.83
Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol (2001) 9.96
Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med (2001) 9.51
alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A (1998) 8.41
Second consensus statement on the diagnosis of multiple system atrophy. Neurology (2008) 7.27
Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology (2009) 7.04
Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A (1998) 6.13
Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol (1997) 6.12
Comparing predictors of conversion and decline in mild cognitive impairment. Neurology (2010) 5.69
Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science (2000) 5.62
A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science (1991) 5.60
Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol (1998) 5.47
Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol (1999) 4.98
MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain (2009) 4.51
Relationships between biomarkers in aging and dementia. Neurology (2009) 4.16
Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol (1996) 4.10
Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science (1998) 4.07
A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem (2000) 3.97
Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci (2000) 3.90
Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci U S A (2000) 3.86
Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron (1997) 3.73
MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology (2009) 3.72
Identification of two distinct synucleins from human brain. FEBS Lett (1994) 3.61
Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron (1999) 3.49
Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron (1993) 3.45
Epitopes that span the tau molecule are shared with paired helical filaments. Neuron (1988) 3.28
Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett (1998) 3.26
Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res (1994) 3.26
The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. EMBO J (1992) 3.04
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology (2009) 2.83
The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol (1999) 2.73
Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution. Chem Biol (1998) 2.73
CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology (2010) 2.67
Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology (2006) 2.65
Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology (2011) 2.61
Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol (1997) 2.60
The mas oncogene encodes an angiotensin receptor. Nature (1988) 2.53
Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol (1998) 2.47
Tau protein pathology in neurodegenerative diseases. Trends Neurosci (1998) 2.37
Synucleinopathies: clinical and pathological implications. Arch Neurol (2001) 2.36
Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J Biol Chem (1998) 2.32
Nestin expression in embryonic human neuroepithelium and in human neuroepithelial tumor cells. Lab Invest (1992) 2.30
Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc Natl Acad Sci U S A (1999) 2.30
Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology (2000) 2.27
Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Lett (1998) 2.26
Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease. Neurology (2004) 2.23
Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology (2010) 2.20
Induction of alpha-synuclein aggregation by intracellular nitrative insult. J Neurosci (2001) 2.16
Two-stage expression of neurofilament polypeptides during rat neurogenesis with early establishment of adult phosphorylation patterns. J Neurosci (1987) 2.15
Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem (1999) 2.13
Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron (1994) 2.13
Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc Natl Acad Sci U S A (1998) 2.13
Frontotemporal dementia progresses to death faster than Alzheimer disease. Neurology (2005) 2.10
Cognitive and motor assessment in autopsy-proven corticobasal degeneration. Neurology (2007) 2.09
Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions. Proc Natl Acad Sci U S A (1996) 2.08
Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580. FEBS Lett (1999) 2.05
The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci (2000) 2.03
Distinct MRI atrophy patterns in autopsy-proven Alzheimer's disease and frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen (2008) 2.00
Differences in cell-to-cell spread of pathogenic and apathogenic rabies virus in vivo and in vitro. J Virol (1985) 2.00
The abnormal phosphorylation of tau protein at Ser-202 in Alzheimer disease recapitulates phosphorylation during development. Proc Natl Acad Sci U S A (1993) 1.99
Autosomal dominant dementia with widespread neurofibrillary tangles. Ann Neurol (1997) 1.98
A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease. J Neurosci Res (2000) 1.97
Neurofilaments and orthograde transport are reduced in ventral root axons of transgenic mice that express human SOD1 with a G93A mutation. J Cell Biol (1997) 1.95
Vascular variant of prion protein cerebral amyloidosis with tau-positive neurofibrillary tangles: the phenotype of the stop codon 145 mutation in PRNP. Proc Natl Acad Sci U S A (1996) 1.94
Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol (1998) 1.93
Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol (2000) 1.92
Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. Cell Death Differ (1998) 1.92
Differential acute and chronic responses of tumor necrosis factor-deficient mice to experimental brain injury. Proc Natl Acad Sci U S A (1999) 1.91
Transplantation of cryopreserved human embryonal carcinoma-derived neurons (NT2N cells) promotes functional recovery in ischemic rats. Exp Neurol (1998) 1.89
Novel CSF biomarkers for frontotemporal lobar degenerations. Neurology (2010) 1.89
Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J (1998) 1.89
Age-dependent synuclein pathology following traumatic brain injury in mice. Exp Neurol (2003) 1.89
Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filaments. Proc Natl Acad Sci U S A (1997) 1.89
A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphorylation of axin and beta-catenin. FEBS Lett (1999) 1.88
High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands. Am J Hum Genet (1999) 1.87
Effect of SB 203580 on the activity of c-Raf in vitro and in vivo. Oncogene (1999) 1.86
Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging. Neuropathol Appl Neurobiol (2015) 1.86
Epitope map of neurofilament protein domains in cortical and peripheral nervous system Lewy bodies. Am J Pathol (1991) 1.86
Biomarkers for early detection of Alzheimer pathology. Neurosignals (2007) 1.86
Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes. Neurobiol Dis (2000) 1.84
Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Exp Neurol (1994) 1.84
Frequency of tau gene mutations in familial and sporadic cases of non-Alzheimer dementia. Arch Neurol (2001) 1.84
Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology (2004) 1.82
Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol (2001) 1.81
Synergistic activation of SAPK1/JNK1 by two MAP kinase kinases in vitro. Curr Biol (1999) 1.81
Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons. Ann Neurol (2000) 1.80
Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Lett (1998) 1.79
Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol (2000) 1.79
Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J (1995) 1.77
Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia. Ann Neurol (2001) 1.75
Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci U S A (1994) 1.74